Market Research Industry Reports

Vivus Inc (VVUS) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Summary

Vivus Inc (Vivus) is a biopharmaceutical company which develops and commercializes next-generation therapeutics for addressing unmet needs in obesity, sleep apnea, diabetes and sexual health. The companys marketed products include, Qsymia (phentermine and topiramate extended-release), indicated for the chronic weight management in adult patients; and Stendra/Spedra (avanafil), an oral phosphodiesterase type 5, for erectile dysfunction. Its pipeline products include Qsymia for obstructive sleep apnea, nonalcoholic steatohepatitis, diabetes, nonalcoholic fatty liver disease and hyperlipidemia; and Tacrolimus for pulmonary arterial hypertension. Vivus works in partnership with pharmaceutical companies to advance of its product portfolio. It operates through its subsidiaries in the UK, the Netherlands, Ireland and Bermuda. Vivus is headquartered in Campbell, California, the US.

Vivus Inc (VVUS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 4
List of Figures 4
Vivus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vivus Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Vivus Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vivus Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Vivus Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Vivus Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
VIVUS Acquires Assets from Janssen Pharma for USD135 Million 10
Vivus Acquires Topiramate Related Patents from Janssen Pharma 11
Venture Financing 12
Athyrium Opportunities Invests in Vivus 12
Partnerships 13
Vivus Plans To Enter Into Co-Marketing Agreement For Qsymia 13
Licensing Agreements 14
VIVUS Enters into Licensing Agreement with Selten Pharma 14
Hetero Enters into Licensing Agreement with VIVUS for STENDRA 15
Metuchen Pharma Enters into Licensing Agreement with Vivus 16
Vivus Enters Into Licensing Agreement With Menarini For Spedra 17
Equity Offering 19
VIVUS Completes Public Offering Of Common Stock For US$202 Million 19
Debt Offering 21
Vivus to Raise Funds through public offering of 4.5% Convertible Bonds Due 2020 21
Vivus Completes Private Placement of Notes Due 2020 For US$220 Million 22
Acquisition 23
Aspen Investment Plans to Acquire Remaining Interest in Vivus for USD640 Million 23
Vivus Inc - Key Competitors 24
Vivus Inc - Key Employees 25
Vivus Inc - Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Financial Announcements 27
May 08, 2018: VIVUS Reports First Quarter 2018 Financial Results 27
Mar 13, 2018: VIVUS Reports Fourth Quarter 2017 Financial Results 29
Nov 07, 2017: VIVUS Reports Third Quarter 2017 Financial Results 31
Aug 03, 2017: VIVUS Reports Second Quarter 2017 Financial Results 33
May 03, 2017: VIVUS Reports 2017 First Quarter Financial Results 35
Mar 08, 2017: VIVUS Reports Fourth Quarter and Full Year 2016 Financial Results 36
Corporate Communications 38
Dec 26, 2017: VIVUS Announces Change in Leadership 38
May 24, 2017: Thomas B. King Joins VIVUS Board of Directors 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40

List Of Tables

List of Tables
Vivus Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Vivus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vivus Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Vivus Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vivus Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Vivus Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
VIVUS Acquires Assets from Janssen Pharma for USD135 Million 10
Vivus Acquires Topiramate Related Patents from Janssen Pharma 11
Athyrium Opportunities Invests in Vivus 12
Vivus Plans To Enter Into Co-Marketing Agreement For Qsymia 13
VIVUS Enters into Licensing Agreement with Selten Pharma 14
Hetero Enters into Licensing Agreement with VIVUS for STENDRA 15
Metuchen Pharma Enters into Licensing Agreement with Vivus 16
Vivus Enters Into Licensing Agreement With Menarini For Spedra 17
VIVUS Completes Public Offering Of Common Stock For US$202 Million 19
Vivus to Raise Funds through public offering of 4.5% Convertible Bonds Due 2020 21
Vivus Completes Private Placement of Notes Due 2020 For US$220 Million 22
Aspen Investment Plans to Acquire Remaining Interest in Vivus for USD640 Million 23
Vivus Inc, Key Competitors 24
Vivus Inc, Key Employees 25
Vivus Inc, Subsidiaries 26

List Of Figures

List of Figures
Vivus Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Vivus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Vivus Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Vivus Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Vivus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vivus Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Vivus Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vivus Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Vivus Inc (VVUS) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Vivus Inc (Vivus) is a biopharmaceutical company which develops and commercializes next-generation therapeutics for addressing unmet needs in obesity, sleep apnea, diabetes and sexual health. The companys marketed products include,

USD 250View Report

VIVUS Inc Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

VIVUS Inc Company Profile is a detailed strategic and analytical report on VIVUS Inc. The 2018 version of the report offers detailed insights into the companys strategies, developments, outlook and

USD 200View Report

VIVUS Inc Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

VIVUS Inc Company Profile is a detailed strategic and analytical report on VIVUS Inc. The 2018 version of the report offers detailed insights into the companys strategies, developments, outlook and

USD 200View Report

Vivus Inc (VVUS) - Financial and Strategic SWOT Analysis Review

Vivus Inc (VVUS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by GlobalData

USD 125View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 250
  • Site Licence    USD 500
  • Enterprise Wide Licence    USD 750
$ 250

Reports Details

Published Date : Jul 2018
No. of Pages :40
Country :United States of America
Category :Company Profiles
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube